Tag Archives: Senator Coons

From Genes to Machines: PERA’s First Full-Committee Hearing

by Dennis Crouch

On July 14, 2026, the full Senate Judiciary Committee held its hearing "From Genes to Machines: The Patent Eligibility Debate," which Chairman Chuck Grassley described as the first time the whole committee, rather than Senator Thom Tillis's Intellectual Property Subcommittee, has taken up the Patent Eligibility Restoration Act of 2025, S. 1546, 119th Cong. (2025) (companion H.R. 3152). PERA would erase the judicial exceptions to Section 101 that the Supreme Court expanded in Alice and Mayo, and replace them with a narrow statutory list of things that cannot be patented. No vote or markup was scheduled, and Grassley was candid that many members are still studying the bill (i.e., do not yet support the legislation).

Tillis, who is retiring at the end of this Congress, said he is willing to change PERA's human-gene language, and he asked Debra Leonard, the witness most opposed to aspects of the bill to send him wording that would, in her view, preserve Myriad.

Four witnesses testified, split evenly. Andrei Iancu (former USPTO Director) and Sue Peschin (Alliance for Aging Research) urged passage. J. John Lee (Computer and Communications Industry Association) and Dr. Leonard (Professor Emerita of Pathology at the University of Vermont and a past president of the Association for Molecular Pathology, the named plaintiff in Myriad) asked the committee to leave current law alone.  I found Dr. Leonard's discussion of gene patenting outdated at this point - that gold rush is over.  The isolated natural sequences behind her 1990s licensing letters have long since been sequenced and published, and those patents are expired, so a fresh claim to one would fail for want of novelty or nonobviousness, whatever Myriad says at the eligibility threshold. What is worth claiming today runs the other way, toward the engineered constructs she herself credited, CRISPR edits and gene therapies, and the cDNA that Myriad already treats as eligible.  But, she also mentioned basic correlations associated with human health - the diagnostic discoveries that continue to be ripe areas for research and that are largely blocked by Mayo.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

The RESTORE Patent Rights Act: One Little Sentence that Could Change Everything

by Dennis Crouch

The Senate Judiciary Committee’s Subcommittee on Intellectual Property recently held a new hearing focusing on the RESTORE Patent Rights Act, a deceptively simple one-sentence bill that could dramatically reshape patent enforcement in the United States. The hearing highlighted the stark divide between those who believe stronger injunctive relief is needed to protect patent rights and those who warn that presumptive injunctions could harm innovation.

At its core, the RESTORE Act would establish a rebuttable presumption that courts should grant permanent injunctions when patent infringement is found. The key language is as follows:

If . . . the court enters a final judgment finding infringement of a right secured by patent, the patent owner shall be entitled to a rebuttable presumption that the court should grant a permanent injunction with respect to that infringing conduct.

This would partially reverse the Supreme Court’s 15-year-old decision in eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006) which eliminated the near-automatic granting of injunctions in patent cases and instead required courts to apply a four-factor test considering irreparable harm, adequacy of monetary damages, balance of hardships, and the public interest.  Under the proposal, the four factors would (I presume) continue to apply, but with the burden shifted to adjudged infringers to show that they do not support injunctive relief.  In my mind, the bill also highlights an aspect of eBay that is not much discussed. The Supreme Court said nothing explicit about whether a presumption of irreparable harm persists — that elimination of even a presumption of irreparable harm came from the Federal Circuit most notably in Robert Bosch LLC v. Pylon Mfg. Corp., 659 F.3d 1142 (Fed. Cir. 2011).  In Bosch, the Federal Circuit took the additional step of interpreting eBay to eliminate the presumption of irreparable harm.  Overruling Smith Int’l, Inc. v. Hughes Tool Co., 718 F.2d 1573 (Fed. Cir. 1983) (“where validity and continuing infringement have been clearly established, immediate irreparable harm is presumed.”).

The December 18, 2024 hearing was led by Senators Coons and Tillis and included four witnesses.

(more…)

Senate Committee Advances PREVAIL Act

by Dennis Crouch

In a tight 11-10 vote, the Senate Judiciary Committee approved the PREVAIL Act (Promoting and Respecting Economically Vital American Innovation Leadership Act) that would make substantial changes to Patent Trial and Appeal Board (PTAB) proceedings. The bill addresses perceived anti-patentee imbalances in the current inter partes review (IPR) system. However, a number of Senators raised concerns and were seeking assurances about a negative impact on generic drug prices. The Bill as adopted by the Judiciary Committee included a friendly amendment by the Bill's co-sponsor Sen. Coons that attempted to address some of the drug-pricing concerns by expanding the scope of who can file IPR/PGR petitions. In particular, the original bill allowed only those sued or accused of infringement to challenge patents. As discussed below, the new approach is designed to enable petitions by generic-drug makers and non-profit patient groups. The major changes in the bill include raising the burden of proof to "clear and convincing evidence," implementing strict timing requirements for PTAB decisions, requiring greater independence of PTAB judges, establishing a "single forum" rule preventing parallel validity challenges, and strengthening estoppel provisions against repeat challenges.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Presumption of Injunction: How the RESTORE Act Aims to Re-Empower Patent Holders

by Dennis Crouch

For the vast majority of American history, a judgment of patent infringement (by a court sitting in equity) led almost directly to injunctive relief barring ongoing infringement.  This construct was flipped by the Supreme Court's 2006 decision in eBay Inc. v. MercExchange, L.L.C., 547 U.S. 388 (2006), a case which served as the first major step of weakening patentee rights over the past two decades.  Now, a new bipartisan bill aims to restore the pre-eBay status quo. The Realizing Engineering, Science, and Technology Opportunities by Restoring Exclusive (RESTORE) Patent Rights Act of 2024, introduced by Senators Coons (D-Del.) and Cotton (R-Ark.), with a House companion bill from Representatives Moran (R-Texas) and Dean (D-Pa.), seeks to reshape and repair the availability of injunctive relief for patent holders.  As you'll see, one nice element of the Bill is that it simply adds 1 sentence - creating a rebuttable presumption


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Improving Efficiency to Increase Competition Act: Burdens of Bayh-Dole

by Dennis Crouch

The Leading pro-IP Senators, Thom Tillis (R-NC) and Chris Coons (D-DE) recently introduced a bill focusing on patents stemming from research paid-for by federal grants. The proposed legislation, titled the “Improving Efficiency to Increase Competition Act,” would require a government study on reporting requirements related to the landmark Bayh-Dole Act of 1980.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

Patent Eligibility Jurisprudence

The USPTO is seeking comments on "the state of patent eligibility jurisprudence" and how eligibility law impacts both innovation and investment-in-innovation.  The deadline for submissions is October 15, 2021..

The USPTO is planning a report to Congress and the agency is hoping that these comments will serve as fundamental building blocks for the report.


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.

USPTO Oversight Hearing by Senate Judiciary Committee

New USPTO Director Andrei Iancu testified in Congress on April 18 for the first time in his new official capacity -- this time before the Senate Judiciary Committee.  The Director must certainly be a visionary -- as the chief guide of U.S. intellectual property policy.  At the same time, the Director is head of a multi-billion-dollar agency with 12,000+ employees.

Although not speaking for the Senate as a whole, Senator Coons kicked-off the hearing with a statement that AIA Trials: "The current review system is systematically biased against patent owners."  From Senator Coon's perspective, the AIA was designed to give the USPTO Director authority to "fine-tune" the AIA trial proceedings without further congressional actions -- and that Director Iancu should take this opportunity to correct the imbalance.

One key statement from Director Iancu is that he is ready to work with Congress on legislative solutions to the "uncertainty" created by Supreme Court 101 jurisprudence.

The following is the Director's Opening Statement: 


To continue reading, become a Patently-O member. Already a member? Simply log in to access the full post.